Recent News for DARE - Dare Bioscience, Inc.

Date Title
Oct 19 Stocks To Watch: Blue Chips Join The Earnings Parade
Oct 14 Daré Bioscience to Participate in Two Upcoming Investor Conferences
Oct 10 Daré Bioscience Announces a Poster Presentation on a Pharmacokinetic Study of DARE-FRT1, in Development for Sustained-Release Progesterone Therapy for Pregnancy Maintenance, at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo
Oct 7 Daré Bioscience to Present an Overview on its Intravaginal Ring (IVR) Technology in Development for Sustained-Release Hormone Therapy and Pregnancy Maintenance at the 9th Annual Partnership Opportunities in Drug Delivery Conference
Sep 11 Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Pharmaceutics
Sep 9 Could The Daré Bioscience, Inc. (NASDAQ:DARE) Ownership Structure Tell Us Something Useful?
Sep 9 Daré Bioscience Announces Completion of its Content Validity Study to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
Sep 4 Daré Bioscience to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Aug 15 Edited Transcript of DARE earnings conference call or presentation 14-Aug-19 8:30pm GMT
Aug 15 Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q2 2019 Results - Earnings Call Transcript
Aug 14 Dare Bioscience EPS misses by $0.09
Aug 14 Daré Bioscience Reports Second Quarter 2019 Financial Results and Company Update
Aug 14 The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering
Aug 12 Daré Bioscience Rallies On FDA Designation For Bacterial Vaginosis Drug
Aug 12 Daré Bio up 8% premarket on QIDP tag for DARE-BV1
Aug 12 Daré Bioscience Receives QIDP Designation from the FDA for DARE-BV1 for the Treatment of Bacterial Vaginosis
Aug 11 The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO
Aug 9 31 Healthcare Stocks Moving In Today's Pre-Market Session
Aug 8 Daré Announces Presentation of Positive Clinical Findings for Vaginal Administration of Novel Formulation of Clindamycin Phosphate for the Treatment of Bacterial Vaginosis at the 2019 Annual Meeting of the Infectious Diseases Society for Obstetrics and...
Aug 6 Daré Bioscience to Host Second Quarter 2019 Financial Results and Company Update Conference Call and Webcast
Jul 22 Daré Announces Presentation of Two Posters at the 2019 Controlled Release Society Annual Meeting & Exposition
Jul 17 Daré Bioscience Announces 2019 AAPS Best Abstract Award for Vaginal Tamoxifen for Treatment of Vulvovaginal Atrophy: Pharmacokinetics and Safety in a Rabbit Model
Jul 15 Daré Bioscience Announces Appointment of Dr. William H. Rastetter as Chairman of the Board of Directors
Jul 11 The Daré Bioscience (NASDAQ:DARE) Share Price Is Down 35% So Some Shareholders Are Getting Worried
Jun 26 Daré Bioscience completes enrollment in pre-pivotal Ovaprene study
Back to the Main DARE Page...